Trials / Completed
CompletedNCT02111954
Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients
PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- University of Lausanne Hospitals · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Prostate cancer patients for whom a F-18-FCH PET/CT is indicated. Ga-68-NODAGA-MJ9 is a new PET/CT radiotracer aiming at giving complementary information : more precise images and early localisation of recurrence to standard imaging
Detailed description
Patient with primary or relapsing prostate cancer for whom F-18-FCH PET/CT is indicated will be proposed to participate to the present study. After signing the patient informed consent, both F-18-FCH and Ga-68-NODAGA-MJ9 PET/CT will be scheduled with a maximum 10 day-interval. No adverse events are expected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9 | Each patient will have two PET/CT |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2016-10-28
- Completion
- 2016-10-28
- First posted
- 2014-04-11
- Last updated
- 2017-05-23
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT02111954. Inclusion in this directory is not an endorsement.